LCM
PVLA

Legato Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Legato Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2M Buy
16,023
+4,638
+41% +$484K 0.18% 168
2025
Q4 		$1.19M Buy
+11,385
New +$971K 0.1% 309

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Legato Capital Management's PVLA Position: Q1 2026 in Review

Legato Capital Management increased its Palvella Therapeutics (PVLA) stake by 41% in Q1 2026, buying an estimated $484K and bringing the position to 16,023 shares worth $2M. The position accounts for 0.18% of the portfolio, ranked #168.

Legato Capital Management first reported a position in PVLA in Q4 2025 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Legato Capital Management held 16,023 shares of Palvella Therapeutics worth $2M as of Q1 2026.
  • Legato Capital Management bought 4,638 Palvella Therapeutics shares in Q1 2026, an estimated $484K.
  • Palvella Therapeutics made up 0.18% of Legato Capital Management's portfolio in Q1 2026, its #168 holding.
  • Legato Capital Management first reported a position in Palvella Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.